Oral Drug Product Strategies and Considerations for Quick to Clinic and Quick to Market

Drug development timelines are shortened by the corporate and clinical strategies of biotech and pharmaceutical companies to achieve proof-of-concept or to rapidly get to the market. For new drug entities entering clinical trials, selecting the right drug product depends on many factors, including the corporate and clinical strategy, and the physiochemical properties of the drug substance. This episode will consider time and cost for developing and compounding or manufacturing the different types of oral drug products dosed in early clinical trials.